tiprankstipranks
Trending News
More News >
HOYA CORPORATION (HOCPY)
OTHER OTC:HOCPY
Advertisement

HOYA (HOCPY) AI Stock Analysis

Compare
34 Followers

Top Page

HOCPY

HOYA

(OTC:HOCPY)

Rating:78Outperform
Price Target:
$141.00
▲(6.88% Upside)
HOYA's strong financial performance is the primary driver of its stock score, supported by robust profitability and a solid balance sheet. Technical indicators suggest moderate bullish momentum, while the valuation reflects a high P/E ratio, indicating expectations of future growth. The absence of earnings call data and notable corporate events means these factors do not influence the score.

HOYA (HOCPY) vs. SPDR S&P 500 ETF (SPY)

HOYA Business Overview & Revenue Model

Company DescriptionHOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and medical related products, such as prosthetic ceramic fillers and metallic implants. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke that is a time and attendance management service, and Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHOYA generates revenue through multiple streams, primarily from its Life Care and Electronics segments. In the Life Care segment, significant revenue comes from the sale of intraocular lenses for cataract surgery and other ophthalmic products, as well as dental products and health-related services. The Electronics segment primarily earns revenue through the production of photomasks and other critical components used in semiconductor manufacturing, catering to the growing demand for advanced electronics. Additionally, HOYA has established partnerships with various healthcare institutions and technology companies, enhancing its market reach and driving sales growth. The company's diverse portfolio and strong R&D capabilities also contribute to its financial performance, enabling it to innovate and meet evolving market needs.

HOYA Financial Statement Overview

Summary
HOYA exhibits strong financial health across all verticals, driven by effective revenue growth, robust profitability, minimal leverage, and solid cash flow generation. The company's financial position is fortified by high equity levels and substantial cash reserves, positioning it well for sustained growth and resilience against economic challenges. Despite minor fluctuations in growth rates and cash flow metrics, the overall financial trajectory remains positive and stable.
Income Statement
85
Very Positive
HOYA demonstrates strong profitability with robust gross profit and net profit margins across the years. The company has shown consistent revenue growth, achieving an impressive revenue growth rate from 2024 to 2025, indicating solid market demand and operational efficiency. The EBIT and EBITDA margins are also healthy, reflecting effective cost management. However, the growth rate between 2020 and 2021 was less pronounced, suggesting some variability in revenue expansion.
Balance Sheet
90
Very Positive
HOYA's balance sheet is notably strong, characterized by a high equity ratio indicating substantial shareholder funding compared to total assets. The debt-to-equity ratio is low, highlighting minimal leverage and reduced financial risk. Return on equity is strong, showcasing effective management in generating returns from shareholder investment. The company's substantial cash reserves further enhance financial stability.
Cash Flow
80
Positive
The cash flow statement reflects a positive trajectory, with consistent free cash flow generation supporting the company's growth initiatives. The operating cash flow to net income ratio is favorable, indicating efficient conversion of earnings into cash. Although the free cash flow growth rate varies across years, the overall trend is upward, suggesting prudent capital expenditure management. A minor point of concern is the fluctuation in investing cash flow, which could impact future profitability.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue885.82B762.61B734.10B670.33B558.26B
Gross Profit766.25B421.69B631.86B567.28B474.98B
EBITDA310.00B285.70B259.78B243.96B200.27B
Net Income202.10B181.38B168.64B164.51B125.45B
Balance Sheet
Total Assets1.23T1.20T1.03T992.84B853.29B
Cash, Cash Equivalents and Short-Term Investments538.53B525.16B426.27B426.63B338.79B
Total Debt37.28B29.24B24.58B21.60B20.75B
Total Liabilities262.65B241.36B213.72B203.78B180.88B
Stockholders Equity974.02B967.76B818.32B803.85B688.00B
Cash Flow
Free Cash Flow187.19B181.73B168.36B161.18B120.57B
Operating Cash Flow235.11B222.80B201.83B190.06B151.81B
Investing Cash Flow-33.19B-35.81B-47.50B-29.30B-29.79B
Financing Cash Flow-190.35B-110.89B-194.59B-106.72B-115.67B

HOYA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price131.92
Price Trends
50DMA
121.92
Positive
100DMA
119.06
Positive
200DMA
123.39
Positive
Market Momentum
MACD
2.75
Negative
RSI
58.82
Neutral
STOCH
79.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Positive. The current price of 131.92 is above the 20-day moving average (MA) of 128.12, above the 50-day MA of 121.92, and above the 200-day MA of 123.39, indicating a bullish trend. The MACD of 2.75 indicates Negative momentum. The RSI at 58.82 is Neutral, neither overbought nor oversold. The STOCH value of 79.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOCPY.

HOYA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$41.71B29.9725.86%0.77%9.84%37.48%
78
Outperform
$17.70B36.8817.72%0.34%2.88%-5.50%
78
Outperform
$45.02B32.9821.19%0.70%9.69%9.99%
73
Outperform
$14.62B35.545.15%6.88%21.11%
65
Neutral
¥343.60B11.19-0.17%2.41%9.60%-12.34%
56
Neutral
$1.41B55.81-25.55%-32.59%-667.81%
55
Neutral
$5.15B-4.22%8.81%40.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HOCPY
HOYA
131.92
0.07
0.05%
COO
Cooper Co
73.26
-21.96
-23.06%
RMD
Resmed
284.89
55.58
24.24%
STAA
Staar Surgical
28.37
-9.92
-25.91%
WST
West Pharmaceutical Services
246.20
-54.55
-18.14%
BLCO
Bausch + Lomb Corporation
14.55
-1.50
-9.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025